Sunlenca Enrollment Form



 Fax Referral To: 1-877-733-3199
 Phone: 1-877-602-5889

 Email Referral To: Customer.ServiceFax@CVSHealth.com
 Phone: 1-877-602-5889

| | Six Si | mple Steps to Submitting | g a Referra | | |
|--|-----------------------------|---|------------------------|--|--|
| PATIENT INFORMA | TION (Complete or i | nclude demographic shee | t) | | |
| | | | | Gender: 🗌 Male 🔲 Female | |
| Address: | City, State, ZIP Code: | | | | |
| Preferred Contact Methods: | Phone (to primary # provide | ed below) 🗌 Text (to cell # prov | ided below) 🗌 |] Email (to email provided below) | |
| • • • • • • | , <u>,</u> | | | enting to receive automated calls, emails and/or | |
| | | | ndard data rat | es apply. Message frequency varies. If unable to | |
| contact via text or email, Special Primary Phone: | | | to Phono: | | |
| Email: | | Alternate Phone: Last Four of SSN: Primary Language: | | | |
| | Name (Last, First): | Relationship | to patient: | | |
| B | | | | | |
| 2 PRESCRIBER INFOR | MATION | | | | |
| Prescriber's Name: | | Sta | te License # | : | |
| NPI #: | DEA #: | Group or Hos | Group or Hospital: | | |
| Address: | | City, State, ZIP Code: | City, State, ZIP Code: | | |
| Phone: | Fax | Contact Person: | | Contact's Phone: | |
| | | | | | |
| S INSURANCE INFORM | ATION Please fax cor | ov of prescription and insuran | ice cards wit | h this form, if available (front and back) | |
| Is the Patient Insured? □ Ye | - | | | | |
| | | | | _ Relationship to Patient: | |
| Medical Insurance: | | Telephone: Pol | icy ID: | Group #: | |
| Prescription Insurance: | | Prescrir | otion Plan Te | aroup # | |
| Policy ID: | Group # | RX B | IN #: | lephone: RX PCN #: | |
| □ Check box if patient is enr | olled in manufacturer co | pay assistance If yes, please | e provide ID# | # | |
| | | | | | |
| 4 DIAGNOSIS AND CLI | NICAL INFORMAT | ION | | | |
| | | | er. | | |
| 10000 by Date: | omp to | | | | |
| | | | | | |
| Diagnosis (ICD-10): | | | | | |
| B20 Human Immunodefic | | | | | |
| Other Code: | Description: | | | | |
| | | | | | |
| Patient Clinical Informat | | | | | |
| Allergies: | | | | | |
| NKDA | | | | | |
| Treatment atotics | | | | | |
| Treatment status: | union of the ran " Data | of loot trootmost (| 1 | | |
| | | of last treatment/ | ./ | | |
| CD4 Count Viral load | l | | | | |

Sunlenca Enrollment Form

| | | Complete Patient and Prescriber | | |
|--|--------------------|--|----------------|--|
| | | _ Patient DOB: F | Patient Phone: | |
| | | | | |
| | | Prescriber Phone: | | |
| 5 PRESCRIPTIC | INFORMATION | | | |
| MEDICATION | STRENGTH | DOSE & DIRECTIONS | | QUANTITY/REFILLS |
| Sunlenca 300 mg tablets 463.5 mg/1.5 mL vials Coording dose Option 1 927 mg by subcutaneous injection (2 x 1.5 mL injections) at 600 mg orally (2 x 300 mg tablets) on Day 1 Then 600 mg orally (2 x 300 mg tablets) on Day 2 Coording dose Option 2 600 mg orally (2 x 300 mg tablets) on Day 1 600 mg orally (2 x 300 mg tablets) on Day 1 600 mg orally (2 x 300 mg tablets) on Day 2 300 mg orally (2 x 300 mg tablets) on Day 2 300 mg orally (1 x 300 mg tablets) on Day 3 Then 927 mg by subcutaneous injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) Image: State of the last injection (2 x 1.5 mL injections) <td rowspan="2">- ·</td> <td>927 mg by subcutaneous injection (2 x 1.5 r 600 mg orally (2 x 300 mg tablets) on Day</td> <td>1</td> <td>Loading dose 1 Quantity: (1) 300 mg-4 tablet blister pack (1) Injection dosing kit (contains 2 vials)</td> | - · | 927 mg by subcutaneous injection (2 x 1.5 r 600 mg orally (2 x 300 mg tablets) on Day | 1 | Loading dose 1 Quantity: (1) 300 mg-4 tablet blister pack (1) Injection dosing kit (contains 2 vials) |
| | | 600 mg orally (2 x 300 mg tablets) on Day 600 mg orally (2 x 300 mg tablets) on Day 300 mg orally (1 x 300 mg tablet) on Day 8 Then 927 mg by subcutaneous injection (2 | 2 | Refills: <u>0</u> Loading dose 2 Quantity: (1) 300 mg-5 tablet blister pack (1) Injection dosing kit (contains 2 vials) Refills: <u>0</u> |
| | , , | Maintenance Quantity: (<u>1</u>) Injection dosing kit (contains 2 vials) Refills: <u>1</u> | | |

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

| | | May Substitute / Product Selection Permitted / Substitution Permissible | |
|-------------------------|-------|--|-------|
| Prescriber's Signature: | Date: | Prescriber's Signature: | Date: |
| | | | |

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _ _____ ATTN: New York and Iowa providers, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.